Yuyu Pharma

At a glance

Yuyu Pharma filed 27 disclosures in the last 12 months, including 5 5% holder, 1 insider and 1 buyback. The most recent key filing was on Jul 21.

Revenue for 2025 was ₩141B, up 5.8% on 2024. Operating margin was 7.8% against 8.8% a year earlier. Debt was 47% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩72.2B and operating profit of ₩8.3B.

The 2025 annual report lists 248 employees with an average tenure of 5.9 years and average pay of ₩61.3M, #909 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩254M each on average. It paid ₩115 per common share in cash dividends, against ₩100 a year earlier (+15%). 유원상 and related parties held 33.25% at year end.

From the 2025 annual report

Staff: 248 (160 men, 88 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩15.4B. Directors and auditors: 5, paid ₩1.3B in total.

Dividends (common shares)

Largest shareholder

유원상 holds 15.13%; with 12 related parties the group holds 33.25% of common shares at year end (from 33.24% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary